M
Marc Teichmann
Researcher at French Institute of Health and Medical Research
Publications - 50
Citations - 7783
Marc Teichmann is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Primary progressive aphasia & Medicine. The author has an hindex of 19, co-authored 43 publications receiving 5238 citations. Previous affiliations of Marc Teichmann include ICM Partners & Pierre-and-Marie-Curie University.
Papers
More filters
Journal ArticleDOI
New advances in the Clinica software platform for clinical neuroimaging studies
Alexandre Routier,Arnaud Marcoux,Mauricio Diaz Melo,Jérémy Guillon,Jorge Samper-González,Junhao Wen,Simona Bottani,Alexis Guyot,Elina Thibeau-Sutre,Marc Teichmann,Marie-Odile Habert,Stanley Durrleman,Ninon Burgos,Olivier Colliot +13 more
Journal ArticleDOI
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois,Harald Hampel,Harald Hampel,Howard Feldman,Philip Scheltens,Paul S. Aisen,Sandrine Andrieu,Hovagim Bakardjian,Habib Benali,Lars Bertram,Lars Bertram,Kaj Blennow,Karl Broich,Enrica Cavedo,Sebastian J. Crutch,Jean-François Dartigues,Charles Duyckaerts,Stéphane Epelbaum,Giovanni B. Frisoni,Serge Gauthier,Remy Genthon,Alida A. Gouw,Alida A. Gouw,Marie-Odile Habert,David M. Holtzman,Miia Kivipelto,Miia Kivipelto,Simone Lista,José Luis Molinuevo,Sid E. O'Bryant,Gil D. Rabinovici,Christopher C. Rowe,Stephen Salloway,Lon S. Schneider,Reisa A. Sperling,Reisa A. Sperling,Marc Teichmann,Maria C. Carrillo,Jeffrey L. Cummings,Cliff R. Jack +39 more
TL;DR: An updated review of the literature and evidence on the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage of Alzheimer's disease are provided.
Journal ArticleDOI
Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study
Bruno Dubois,Stéphane Epelbaum,Francis Nyasse,Hovagim Bakardjian,Geoffroy Gagliardi,Olga Uspenskaya,Marion Houot,Simone Lista,Federica Cacciamani,Marie-Claude Potier,Anne Bertrand,Foudil Lamari,Habib Benali,Jean-François Mangin,Olivier Colliot,Remy Genthon,Marie-Odile Habert,Harald Hampel,Christelle Audrain,Alexandra Auffret,Filippo Baldacci,Ismahane Benakki,Hugo Bertin,Laurie Boukadida,Enrica Cavedo,Patrizia A. Chiesa,Luce Dauphinot,Antonio Melo dos Santos,Marion Dubois,Stanley Durrleman,Gaëlle Fontaine,Alexis Genin,Pauline Glasman,Navichka Jungalee,Aurélie Kas,Maya Kilani,Valentina La Corte,Stéphane Lehéricy,Claire Letondor,Marcel Levy,Mark Lowrey,Juliette Ly,Ornella Makiese,Christiane Metzinger,Agnès Michon,Fanny Mochel,Catherine Poisson,Stephie Ratovohery,Marie Revillon,Katrine Rojkova,Perrine Roy,Katia Santos-Andrade,Rachel Schindler,Laure Seux,Valérie Simon,Marine Sole,Caroline Tandetnik,Marc Teichmann,Michel Thiebaut de Shotten,Nadjia Younsi +59 more
TL;DR: The INSIGHT-preAD study as discussed by the authors assessed associations between brain β-amyloidosis and various cognitive and neuroimaging parameters with progression of cognitive decline in individuals with preclinical Alzheimer's disease.
Journal ArticleDOI
Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation
Marc Teichmann,Aurélie Kas,Claire Boutet,Sophie Ferrieux,Marie Nogues,Dalila Samri,Christina Rogan,Didier Dormont,Didier Dormont,Bruno Dubois,Raffaella Migliaccio,Raffaella Migliaccio +11 more
TL;DR: Logopenic aphasia due to probable Alzheimer pathology is a more aggressive variant characterized by more extensive language/cognitive disorders affecting, in addition to lexical processes and verbal working memory, also phoneme sequencing, semantic processing and ideomotor praxis.
Journal ArticleDOI
Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia
David Bergeron,David Bergeron,Maria Luisa Gorno-Tempini,Gil D. Rabinovici,Miguel A. Santos-Santos,William W. Seeley,Bruce L. Miller,Yolande A.L. Pijnenburg,M. Antoinette Keulen,Colin Groot,Bart N.M. van Berckel,Wiesje M. van der Flier,Philip Scheltens,Jonathan D. Rohrer,Jason D. Warren,Jonathan M. Schott,Nick C. Fox,Raquel Sánchez-Valle,Oriol Grau-Rivera,Ellen Gelpi,Harro Seelaar,Janne M. Papma,John C. van Swieten,John R. Hodges,John R. Hodges,John R. Hodges,Cristian E. Leyton,Olivier Piguet,Olivier Piguet,Olivier Piguet,Emily Rogalski,Emily Rogalski,M.-Marsel Mesulam,Lejla Koric,Kristensen Nora,Jeéreémie Pariente,Bradford C. Dickerson,Ian R. A. Mackenzie,Ging-Yuek Robin Hsiung,Serge Belliard,David J. Irwin,David A. Wolk,Murray Grossman,Matthew Jones,Jennifer M. Harris,David G. Mann,Julie S. Snowden,Patricio Chrem-Méndez,Ismael Calandri,Alejandra A. Amengual,Carole Miguet-Alfonsi,Eloi Magnin,Giuseppe Magnani,Roberto Santangelo,Vincent Deramecourt,Florence Pasquier,Niklas Mattsson,Christer Nilsson,Oskar Hansson,Julia Keith,Mario Masellis,Sandra E. Black,Jordi A. Matías-Guiu,María Nieves Cabrera-Martín,Claire Paquet,Julien Dumurgier,Marc Teichmann,Marie Sarazin,Marie Sarazin,Michel Bottlaender,Michel Bottlaender,Bruno Dubois,Christopher C. Rowe,Victor L. Villemagne,Rik Vandenberghe,Elias Granadillo,Edmond Teng,Mario F. Mendez,Philipp T. Meyer,Lars Frings,Alberto Lleó,Rafael Blesa,Juan Fortea,Sang Won Seo,Janine Diehl-Schmid,Timo Grimmer,Kristian Steen Frederiksen,Pascual Sánchez-Juan,Gaël Chételat,Willemijn J. Jansen,Rémi W. Bouchard,Robert Laforce,Pieter Jelle Visser,Rik Ossenkoppele,Rik Ossenkoppele +94 more
TL;DR: To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants, PET/CSF biomarkers are used.